ArticleCancers2019
Monitoring Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR Spectroscopy of Liquid Biopsies.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00951535 (A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0M0 Prostate Cancer), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0M0 Prostate Cancer
Who cites it
12 citing papers in PubMed.
- Beyond Color: Hybrid Vibrational-Electronic Broadband Coherent Anti-Stokes Raman Scattering for Molecularly Informed Digital Pathology.Analytical chemistry · 2026Article
- Metabolomics of Prostate Cancer and Clinical Profiles Following Radiotherapy: Need for a Precision Phylometabolomics Approach.Diagnostics (Basel, Switzerland) · 2025Article
- Modelling of immune infiltration in prostate cancer treated with HDR-brachytherapy using Raman spectroscopy and machine learning.Scientific reports · 2025Article
- Monitoring Biochemical Changes of Neuroblastoma Cells in Early Stages After X-Ray Exposure by Using Fourier-Transform Infrared Spectroscopy.Sensors (Basel, Switzerland) · 2024Article
- Long-term, non-invasive FTIR detection of low-dose ionizing radiation exposure.Scientific reports · 2024Article
- Exploring the Steps of Infrared (IR) Spectral Analysis: Pre-Processing, (Classical) Data Modelling, and Deep Learning.Molecules (Basel, Switzerland) · 2023Review
- Metasurface-enhanced infrared spectroscopy in multiwell format for real-time assaying of live cells.Lab on a chip · 2023Article
- Application of Advanced Non-Linear Spectral Decomposition and Regression Methods for Spectroscopic Analysis of Targeted and Non-Targeted Irradiation Effects in anInternational journal of molecular sciences · 2022Article
- Detection of Prostate Cancer via IR Spectroscopic Analysis of Urinary Extracellular Vesicles: A Pilot Study.Membranes · 2021Article
- Spectroscopic evaluation of carcinogenesis in endometrial cancer.Scientific reports · 2021Article
- New Discoveries in Radiation Science.Cancers · 2021Article
- Vibrational spectroscopy of liquid biopsies for prostate cancer diagnosis.Therapeutic advances in medical oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Radiation therapy (RT) is used to treat approximately 50% of all cancer patients. However, RT causes a wide range of adverse late effects that can affect a patient's quality of life. There are currently no predictive assays in clinical use to identify patients at risk of normal tissue radiation toxicity. This study aimed to investigate the potential of Fourier transform infrared (FTIR) spectroscopy for monitoring radiotherapeutic response. Blood plasma was acquired from 53 prostate cancer patients at five different time points: prior to treatment, after hormone treatment, at the end of radiotherapy, two months post radiotherapy and eight months post radiotherapy. FTIR spectra were recorded from plasma samples at all time points and the data was analysed using MATLAB software. Discrimination was observed between spectra recorded at baseline versus follow up time points, as well as between spectra from patients showing minimal and severe acute and late toxicity using principal component analysis. A partial least squares discriminant analysis model achieved sensitivity and specificity rates ranging from 80% to 99%. This technology may have potential to monitor radiotherapeutic response in prostate cancer patients using non-invasive blood plasma samples and could lead to individualised patient radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.